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ABSTRACT

EVALUATING THE CLINICAL IMPACT OF PROVIDING
HOME BLOOD PRESSURE MONITORS TO PATIENTS WITH
ELEVATED OR HIGH BLOOD PRESSURE
Many clinicians continue to diagnose hypertension based on office-based
readings, despite the 2015 United States Preventive Services Task Force
recommendation for the use of home or ambulatory blood pressure monitoring to
confirm the diagnosis of hypertension prior to initiating treatment. Without
obtaining blood pressure readings outside of the clinic environment, it is
impossible to correctly diagnose hypertension, particularly regarding masked
hypertension and white coat hypertension.
Stanford Health Care implemented a quality improvement project that
provided patients with a home blood pressure device to monitor out of clinic blood
pressure readings. The purpose of the project was to improve clinical care at
Stanford Health Care, to assess for treatment control in patients already diagnosed
with hypertension, and to verify the diagnosis of hypertension in patients
undiagnosed. There were 98 subjects who had elevated or high blood pressure
readings in the clinic who agreed to participate in the project. Findings showed
that home blood pressure monitoring was effective in assessing for hypertension
treatment control and verifying hypertensive phenotype in previously undiagnosed
patients. Home blood pressure monitoring also allowed for timely diagnosis and
treatment of hypertension. Providing home blood pressure devices to patients has
the potential to reduce morbidity and mortality related to hypertension, reduce
economic burden, and contribute to national quality initiatives that contribute to
the overall health of the nation.
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CHAPTER 1: INTRODUCTION
Management of hypertension is a public health challenge. Approximately 1
in 3 United States adults has hypertension (Centers for Disease Control (CDC),
2016). New hypertension screening guidelines published in 2017 by the American
Heart Association (AHA) and the American College of Cardiology (ACC)
aggressively defines hypertension as having a systolic blood pressure (SBP)
greater than 130 mmHg or a diastolic blood pressure (DBP) greater than 80
mmHg. The stricter definition of hypertension resulted in a substantial increase in
prevalence of United States adults with hypertension, which increased from 31.1%
to 45.6% based on data from the 2011 to 2014 National Health and Nutrition
Examination Survey (NHANES) (Muntner et al., 2018). Currently, of the United
States adults with the diagnosis of hypertension, 47.8% have blood pressure
control, which is far below the target of Healthy People 2020’s Leading Health
Indicator initiative of having achieved 61.2% blood of pressure control (Office of
Disease Prevention and Health Promotion (ODPHP), 2019).
Many clinicians continue to diagnose hypertension based on clinic readings
despite the 2015 United States Preventive Services Task Force (USPSTF)
recommendation that out of clinic blood pressure measurements should be
obtained in order to confirm the diagnosis of hypertension before starting
pharmacologic treatment, unless contraindicated (Siu, 2015). The 2017 AHA and
ACC guideline also recommends utilization of home or ambulatory blood pressure
monitoring to confirm the diagnosis of hypertension (Whelton et al, 2018). These
changes were implemented to take into account the limitations to blood pressure
measurement in the clinic setting, including incorrect blood pressure measuring
techniques, improper training of medical staff, limited number of clinic readings
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available to make a definitive diagnosis, and the inability to monitor the natural
changes in blood pressure over a 24-hour period (White & Gulati, 2015).
Furthermore, by relying on clinic blood pressure measurements, it is impossible to
correctly diagnose hypertension, particularly in regard to white coat hypertension
and masked hypertension (Whelton et al., 2018). White coat hypertension refers to
patients having high blood pressure in the clinic, but normal measurements in their
natural environment (Siu, 2015). Masked hypertension is when a patient has
normal blood pressure readings in the clinic, but high measurements in the
ambulatory setting (Siu, 2015). Without home blood pressure monitoring, there is
no way to identify patients with white coat hypertension or masked hypertension,
resulting in misdiagnosis of hypertension.
Stanford Health Care implemented a quality improvement project to
improve clinical care and address the problem of misdiagnosis of hypertension due
to lack of home blood pressure monitoring. Staff created a patient-centered,
standardized blood pressure screening workflow using the health belief model as a
theoretical framework to inform the workflow design. Patients who presented to
the clinic with elevated or high blood pressure readings were provided a home
blood pressure monitor, detailed information about high blood pressure and the
consequences of untreated hypertension, and instruction on how to use the monitor
at home. For patients already diagnosed with hypertension on anti-hypertensive
medication, the home blood pressure monitor was provided to assess for treatment
control. For patients undiagnosed with hypertension, the home blood pressure
monitor was provided to confirm if the patient had normotension, sustained
hypertension, white coat hypertension, or masked hypertension. A retrospective
chart review was performed to evaluate the clinical impact of providing home
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blood pressure monitors to patients with elevated or high blood blood pressure
readings in the clinic setting.
Background and Significance
High blood pressure, or hypertension, is the most common chronic
condition seen in an ambulatory setting in the United States (National Center for
Health Statistics, 2015). Often called the silent killer because there are often no
physical symptoms associated with high blood pressure, the consequence of
untreated hypertension is target organ damage, which includes stroke, vision loss,
heart attack, heart failure, kidney disease, sexual dysfunction, and peripheral
arterial disease (AHA, 2016). In 2014, high blood pressure was a primary or
contributing cause of death in the United States resulting in 1,100 deaths each day
(CDC, 2016). Worldwide, it is estimated that 7.5 million deaths are the result of
hypertension; this represents about 12.8% of all total deaths (World Health
Organization, 2019).
Hypertension is a major modifiable risk factor for cardiovascular disease
and all-cause mortality (Whelton et al, 2018). Modifiable risk factors in patients
with hypertension include cigarette smoking or secondhand smoking, diabetes
mellitus, dyslipidemia, alcohol consumption, being overweight or obese, physical
inactivity, excess stress, and poor diet choices, particularly ones high in sodium
(AHA, 2017; Whelton et al, 2018). Common hereditary and physical risk factors
include the presence of chronic kidney disease, diabetes, family history of
hypertension, increased age, low socioeconomic status, male sex, obstructive sleep
apnea, and psychosocial stress (AHA, 2017; Whelton et al, 2018).
High blood pressure is associated with a heavy economic burden. The cost
of health care services, medications for treatment, and missed days of work related
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to hypertension costs the United States 48.6 billion dollars each year (CDC, 2016).
The AHA projected that the cost of care for hypertension will increase to a total
projected annual cost of 200.3 billion dollars in 2030, which is a 286% increase
from 2010 (Heidenreich et al, 2011).
With the added responsibility of national quality health initiatives pushing
for better blood pressure control, it is crucial that patients who have hypertension
or who are at risk for developing hypertension learn to monitor their blood
pressure at home. Healthy People is a well-known national initiative managed by
the Office of Disease Prevention and Health Promotion. Every ten years, Healthy
People sets measurable objectives and goals driven by best available knowledge
and literature to improve practice and the health of the nation (ODPHP, 2019).
There are six objectives in Healthy People 2020 related to high blood pressure,
one of which is considered a Leading Health Indicator. This priority issue is to
achieve 61.2% blood pressure control amongst United States adults diagnosed
with hypertension. In 2008, only 43.7% of United States adults with hypertension
had their blood pressure under control. The 2013-2016 NHANES data showed
control to only be at 47.8%, far below the target of 61.2% (ODPHP, 2019).
National Guidelines
Over the last twenty years, there have been three guidelines published in
the United States for hypertension prevention and management. The Seventh
Report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 7) was published in 2003 (see Table 1). A
coalition of 39 professional organizations and 7 federal agencies convened to
review observational studies and clinical trials to create a guideline for clinicians
to classify and treat hypertension (Chobanian et al., 2003). Methodology was
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through nonsystematic literature review and recommendations were based on
expert committee consensus (James et al., 2014). Pharmacologic treatment of
hypertension, according to JNC 7, was initiated at Hypertension Stage 1, when the
patient had a SBP of 140 mmHg or a DBP of 90 mmHg, unless they had diabetes
or chronic kidney disease. Patients with diabetes or chronic kidney disease had
more aggressive treatment guidelines in which their goal SBP was less than 130
mmHg and their goal DBP was less than 80 mmHg (Chobanian et al., 2003). The
guideline includes a brief discussion regarding the use of ambulatory or home
blood pressure monitoring to evaluate for white coat hypertension, as well as a
short excerpt on lifestyle modifications (Chobanian et al., 2003). In regard to
pharmacologic treatment, JNC 7 recommended thiazide diuretics as the first-line
treatment for hypertension (Chobanian et al., 2003).
Table 1
2003 JNC 7 Hypertension Guidelines: Blood Pressure Categories
Blood Pressure Category

Systolic (mmHg)

Diastolic
(mmHg)

Normal

Less than 120

AND

Less than 80

Prehypertension

120 – 139

OR

80 - 89

Hypertension Stage 1

140 - 159

OR

90 - 99

Hypertension Stage 2

160 or higher

OR

100 or higher

Hypertensive Crisis

180 or higher

OR

120 or higher

In 2014, the Eighth Joint National Committee (JNC 8) reviewed and
synthesized scientific evidence from randomized controlled trials to revise JNC 7
(James et al., 2014). The definition for hypertension remained the same at a SBP
of 140 mmHg and a DBP of 90 mmHg. The JNC 8 guideline increased the
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threshold goal for patients with diabetes and chronic kidney disease to the same as
the general population, at a SBP of 140 mmHg and a DBP of 90 mmHG (James et
al., 2014). The only group whose goal was different than the general population
were adults 60 years of age or older, in which their goal was specified at a SBP
less than 150 mmHg and a DBP less than 90 mmHg (James et al., 2014). In
addition to thiazide diuretics, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, and calcium channel blockers were added for use as
first-line treatment for hypertension (James et al., 2014).
A systematic review by the AHA, ACC, and the National Heart, Lung, and
Blood Institute (NHLBI) lead to the publication of the 2017 Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults (Whelton et al, 2018). It was intended as an update to the 2003 JNC 7
guideline. The guideline aggressively lowers the threshold for the diagnosis of
hypertension to a SBP of 130 mmHg and a DBP of 80 mmHg in the general
population, despite medical history, age, or comorbidities (see Table 2) (Whelton
et al., 2018). The terminology ‘elevated blood pressure’ replaced
‘prehypertension,’ also with a lower threshold in definition (see Table 2).
Treatment parameters varied, with a large emphasis on lifestyle modifications
through diet, exercise, alcohol restriction, and smoking cessation in all patients
regardless of their blood pressure category (Whelton et al., 2018). This was the
first guideline that recommended calculating the ten-year cardiovascular risk score
when considering pharmacologic treatment for patients with Hypertension Stage 1
(Whelton et al., 2018). This was also the first guideline whose blood pressure
screening workflow included the use of home or ambulatory blood pressure
monitoring to consider the diagnoses of white coat hypertension and masked
hypertension (Whelton et al., 2018).
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Table 2
2017 AHA / ACC Hypertension Guidelines: Blood Pressure Categories
Blood Pressure Category

Systolic

Diastolic

(mmHg)

(mmHg)

Normal

Less than 120

AND

Less than 80

Elevated Blood Pressure

120 – 129

AND

Less than 80

High Blood Pressure (Hypertension)

130 – 139

OR

80 – 89

140 or higher

OR

90 or higher

180 or higher

OR

120 or higher

Stage 1
High Blood Pressure (Hypertension)
Stage 2
Hypertensive Crisis

Theoretical Framework: The Health Belief Model
The health belief model was developed by social psychologists Hochbaum,
Kegels, and Rosenstock in the 1950s (Hochbaum et al, 1952). This was a time
when public health programs were being implemented but underutilized. Despite
the availability of low or no cost health programs, the population was not
participating in preventive initiatives, including influenza and polio vaccinations,
cervical cancer screening, and tuberculosis screening (Rosenstock, 1974). The
health belief model aimed to explain why patients chose to participate in or
withdraw from services by exploring the beliefs and attitudes that influenced
decision making (Hochbaum et al., 1952). Since the 1950s, the health belief model
has evolved beyond utilization in preventive health and has been used to explain
and predict behavior directed toward compliance in treatment of chronic illness.
The health belief model is composed of six main concepts, all of which influence a
person’s readiness to act or change their behavior. These concepts are perceived
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susceptibility, perceived severity, perceived benefits, perceived barriers, cue to
action, and self-efficacy (Glanz et al., 2018).
Specific to hypertension, the health belief model has been used in literature
to study medication adherence, health promotion, and to help inform educational
programs for hypertension. A cross-sectional study in a rural city in Iran found
that only 24% of a sample of 671 participants with hypertension adhered to their
medication regimen (Kamran et al., 2014). The patients more likely to adhere to
their treatment plan were patients who perceived that they were susceptible to
having hypertension, and that the benefit of treatment outweighed their perceived
severity of having hypertension. Results showed the value and importance of
patient perceptions on hypertension and medication. Education should be
individualized and tailored according to patient perceptions in order to improve
medication adherence. Thalacker (2011) used the health belief model as a tool to
understand Hmong culture and what influenced their behaviors related to
hypertension treatment. Through the health belief model, she was able to suggest
an educational program facilitated by health care providers geared to empower the
Hmong people to choose health-promoting behaviors related to hypertension
(Thalacker, 2011).
For this quality improvement project, the health belief model was used as a
theoretical framework to help guide Stanford Health Care’s blood pressure
screening workflow. The health care team evaluated each of the concepts within
the health belief model to inform the design of the blood pressure screening
workflow. In doing so, the workflow was designed to inspire participation in the
quality improvement project, as well as empower patients to actively engaged in
their health by learning how to monitor and understand their blood pressure
readings in hopes to trigger healthy lifestyle choices.
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Perceived Susceptibility and
Perceived Severity
Perceived susceptibility refers to a person’s belief in the likelihood of
having a disease or condition (Glanz et al., 2018). Patients who have hypertension
generally feel well without any noticeable symptoms. Because of this, there is
little motivation for patients who have hypertension, or who are at risk for
developing hypertension, to comply with pharmacologic treatment or lifestyle
modification recommendations. In order for patients to act, they must accept that
they may be susceptible to hypertension and its sequelae. The hypertension
screening workflow takes this into account by educating every participant during
their clinic visit on the meaning of hypertension and the consequences of targetorgan damage if left untreated.
Perceived Benefits and Perceived
Barriers
Perceived benefits refer to the belief that taking action toward prevention or
treatment of disease will reduce a person’s susceptibility or severity of the disease
(Glanz et al., 2018). The treatment for hypertension includes lifestyle
modifications and health promotion in every patient regardless of what stage
hypertension they have. Pharmacologic intervention is recommended in patients
with Hypertension Stage 2, or in patients with Hypertension Stage 1 with certain
comorbidities or a high cardiovascular risk score (Whelton et al., 2018). Treatment
adherence is dependent on the patient believing that the benefits of treatment
outweigh the barriers and risks. The hypertension screening workflow eliminates
three common barriers in home blood pressure monitoring: the out of pocket cost
of a home blood pressure device, the concern of correct usage, and the concern of
accurate calibration (Kronish et al., 2017; Tirabassi et al., 2013). The device is
provided to the patient at no cost, the patient is taught how to utilize the home
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blood pressure device, return demonstration of use in the clinic is encouraged, and
the device calibration is validated against the clinic automated device in the clinic
in front of the patient.
Cue to Action
Cue to action refers to internal or external factors that influence one to take
action (Glanz et al., 2018). The cue to action for this quality improvement project
is the clinic intervention of providing patients with home blood pressure monitors.
As the patient monitors their blood pressure at home, they witness first-hand the
variations in their blood pressure readings, whether they are normal or high. This
awareness cues them to take their blood pressures seriously, prompting them to
make the changes needed to prevent or treat their high blood pressure.
Self-Efficacy
Self-efficacy refers to the confidence in an individual to successfully
perform an action or behavior change (Glanz et al., 2018). Self-efficacy is an
important concept in hypertension management. In giving a patient a home blood
pressure monitor, the clinic promotes self-efficacy by actively engaging the patient
in their health. In promoting self-efficacy, the patient becomes confident in selfcare, has an understanding of their home blood pressure readings and implications
of untreated high blood pressure, and is empowered to execute lasting lifestyle
changes to reduce their cardiovascular risk.

CHAPTER 2: LITERATURE REVIEW
Literature was sought to investigate patient and provider barriers to home
blood pressure monitoring, prevalence and risk factors associated with masked and
white coat hypertension, and the clinical significance for diagnosing masked and
white coat hypertension.
Home and Ambulatory Blood Pressure Devices
There are two approved devices to measure blood pressure readings outside
of the clinic setting: ambulatory blood pressure monitoring (ABPM) and home
blood pressure monitoring (HBPM) (Shimbo et al., 2015). ABPM measures blood
pressure every fifteen to thirty minutes over a 24-hour period during daily routine
activities, whereas, HBPM assesses blood pressure at specific times while the
person is seated and resting. ABPM and HBPM provide data used to calculate
mean out-of-clinic blood pressure in order to identify a person’s hypertensive
phenotype. There are four primary hypertensive phenotypes: normotension,
sustained hypertension, white coat hypertension and masked hypertension
(Shimbo et al., 2015).
The final recommendation statement for high blood pressure screening in
adults from the USPSTF confirms that there is more evidence that supports ABPM
as superior to HBPM; however, if ABPM is unavailable HBPM is an acceptable
alternative (Siu, 2015). Since this statement released in 2015, hypertension
guidelines have increasingly supported the use of HBPM in the management of
hypertension, including the European Society of Hypertension 2018 guideline, the
United States AHA and ACC 2017 guideline, and the United Kingdom National
Institute for Health and Care Excellence guideline (NICE) (Williams et. Al, 2018;
Whelton et al., 2018; NICE, 2019).
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Challenges of Ambulatory Blood
Pressure Monitoring
There are barriers to consider when utilizing ABPM for both the primary
care provider and the patient. Primary care providers voiced concerns regarding
the cost of ABPM, willingness or ability of the patient to successfully complete
testing, and concerns about the accuracy and benefits of testing (Kronish et al.,
2017). ABPM is not widely available in primary care settings, often requiring a
referral to a hypertension center or office that has the capacity to perform the test
(White & Gulati, 2015). Insurance companies do not always reimburse for ABPM
and the reimbursement rate is low (Kent et al., 2014). The perception of primary
care providers regarding the lack of patient willingness for testing is disputed in
Carter et al.’s qualitative study. Patients voiced that having the option for ABPM
or HBPM was an opportunity for them to engage in their care and because of this,
they would agree to testing if recommended by the primary care provider (Carter
et al., 2018). Patients want to actively participate in their health; however, this is
difficult to do without time and resources provided by their primary care. Barriers
described on the patient side included testing reliability and concerns regarding
night-time blood pressure readings as being disruptive (Carter et al., 2018).
Common reported disadvantages from participants who underwent ABPM
included pain, skin irritation, bruising, and interference with sleep, so much so that
some patients removed the device during the night (Viera et al., 2011).
Challenges of Home Blood Pressure
Monitoring
Home blood pressure devices are more widely available than ABPM, as
they can be purchased in retail stores and pharmacies. Like ABPM, there are
barriers to consider in respect to the primary care provider and patient. Primary
care providers voiced concerns regarding compliance with correct methodology
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for blood pressure measurement, accuracy of test results, out of pocket costs for
the devices, and the time needed to instruct patients on home blood pressure
monitoring protocol (Bonafini and Fava, 2015; Kronish et al., 2017). Physicians
also voiced concerns about the use of non-validated HBPM and the potential for
patient preoccupation in blood pressure monitoring which may lead to anxiety
(Cheng et al, 2003; Logan et al., 2008). HBPM allows for more data points over a
longer period of time, which may be an advantage or disadvantage. ABPM only
provides short-term blood pressure variability over 24-hours, which may not be an
appropriate time frame for diagnosis of this chronic condition (Bonafini & Fava,
2015; White & Gulati, 2015). Patients primary concern regarding HBPM was the
out of pocket cost if the device was not covered by insurance (Carter et al., 2018;
CDC, 2013). Because of this, many patients preferred to have ABPM over HBPM
if it was covered by their insurance, to minimize out of pocket costs (Carter et al.,
2018; CDC, 2013).
White Coat Hypertension
Prevalence
White-coat hypertension was first described in United States literature in
1984 (Kleinert et al., 1984). Epidemiologic data through the USPSTF estimates
that 15 to 30% of United States adults have white coat hypertension (Piper et al.,
2015).
Risk Factors
It is proposed that white coat hypertension is due to sympathetic nervous
system activation during encounters with health care providers (Grassi et al.,
2013). Similarly, Bloomfield and Park attribute the white-coat effect to a neuro-
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endocrine reflex conditioned by anticipation of having one’s blood pressure taken
and fear of what the measurement may indicate (2017). Another determinant of
white coat hypertension is age, with patients over the age of 60 at higher risk of
having white coat hypertension compared to younger participants (Tanner et al.,
2016).
Screening
Current USPSTF hypertension screening recommendations and the 2017
AHA and ACC guideline recommends screening for white coat hypertension with
ABPM or HBPM for any patient with elevated or high blood pressure readings in
the clinic setting (Siu, 2015; Whelton et al., 2018).
Masked Hypertension
Prevalence
Masked hypertension is a newly appreciated phenomenon, first mentioned
in United States literature in 2002 (Pickering et al., 2002). Wang et al. pooled data
from the Masked Hypertension study and the NHANES to understand the burden
of masked hypertension on the United States (2017). Based on the data, they
estimated that 12.3% of United States adults have masked hypertension (Wang et
al., 2017). If this data is accurate, then about 1 in every 8 United States adult with
normal or elevated blood pressure in the clinic actually has masked hypertension,
resulting in millions of adults misclassified as not having hypertension. This is the
only study that provides an estimate of masked hypertension prevalence in the
United States. A systematic review of five population-based studies, four in
Europe and one in Japan, found prevalence of masked hypertension in the general
population to range anywhere between 14% to 30% (Peacock et al., 2014).
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Risk Factors
The risk factors for masked hypertension are consistent with the risk factors
for sustained hypertension. The Jackson Heart Study evaluated masked
hypertension in a community-based cohort of African Americans residing in
Jackson, Mississippi (Bromfield et al., 2016). Life’s Simple 7 questionnaire was
used to identify modifiable risk factors and included body mass index (BMI),
physical activity, diet, cigarette smoking, clinic-measured blood pressure, total
cholesterol, and a fasting glucose. Of the participants, 30.5% had masked
hypertension. Masked hypertension was more likely to occur in patients who had
worse overall cardiovascular health: poor physical activity, positive smoking
status, prehypertenion, and poor diet (Bromfield et al., 2016). Similarly, in two
separate studies, persons with a sedentary lifestyle, obesity, and low exercise
tolerance were prone to having masked hypertension (Schultz et al., 2011;
Sharman et al., 2011).
Additionally, alcohol consumption, caffeine consumption, and cigarette
smoking are risk factors for masked hypertension (Franklin et al., 2015). Stress or
job strain also contributed to normal or elevated blood pressure readings in the
clinic but high blood pressure readings outside of the clinic setting (Landsbergis et
al., 2013). Conditions that have been linked to masked hypertension include
metabolic syndrome, diabetes mellitus, chronic kidney disease, and obstructive
sleep apnea (Franklin et al., 2015).
There is conflicting data whether age is a predictor for masked
hypertension. Data solely from the Masked Hypertension Study found that of the
888 healthy, middle-aged, employed participants not on medication for
hypertension, the prevalence of phenotypes was 79.8% with normotension, 14.9%
for masked hypertension, 1.0% with white-coat hypertension, and 4.3% with
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sustained hypertension (Schwartz et al., 2016). The majority of patients with
masked hypertension were young adults (Schwartz et al, 2016). On the other hand,
masked hypertension was found to be more prevalent among older adult males and
in patients with prehypertension or diabetes from data pooled from both the
Masked Hypertension Study and the NHANES (Wang et al., 2017).
A common predictor for masked hypertension was the presence of elevated
blood pressure, formerly known as prehypertension, in the clinic setting (Shimbo
et al., 2012; Redmond et al., 2016). Of the patients diagnosed with masked
hypertension in the Masked Hypertension Study, 35% had a borderline elevated
blood pressure reading in the clinic setting and only 8.9% of the patients had
normal clinic blood pressure measurements (Shimbo et al., 2012). Similarly, of the
patients diagnosed with masked hypertension in the Improving the Detection of
Hypertension Study, 35.3% had elevated blood pressure readings in the clinic
setting compared to 6.8% with normal clinic blood pressure measurements
(Redmond et al., 2016).
Screening
Literature does not offer clear criteria on whom to screen to detect masked
hypertension. Data was pooled from the Masked Hypertension Study, the
Improving the Detection of Hypertension Study, and the Jackson Heart Study to
determine the practicality of what parameters to use to screen for masked
hypertension (Booth et al., 2016). Screening all patients with normal clinic blood
pressure readings would result in 118.6 million (~78%) United States adults to
undergo ABPM. On the other hand, if elevated clinic blood pressure was used as
the criterion to screen for masked hypertension, 59.3 million (~39%) United States
adults wound undergo ABPM. If the upper range of prehypertension was used as
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the criterion for masked hypertension screening, then 20.3 million (13%) United
States adults would undergo ABPM. Alternatively, instead of using clinic blood
readings as the sole criterion for masked hypertension screening, the practitioner
can take a different approach by only screening patients who have more risk
factors associated with masked hypertension (Booth et al., 2016). At this point, the
ACC/AHA guideline recommends screening patients for masked hypertension
using ABPM or HBPM if there is suspicion for masked hypertension and the
patient has elevated blood pressure readings in the clinic (a SBP between 120 to
129 mmHg and a DBP less than 80 mmHg) (Whelton et al., 2017).
Clinical Significance of White Coat Hypertension
and Masked Hypertension
Masked hypertension is associated with increased adverse cardiovascular
outcomes and target organ damage. Patients within the Jackson Heart Study who
had masked hypertension compared to normotension had increased arterial,
cardiac, and renal damage compared to patients with normotension as measured by
carotid artery intimedia thickness, left ventricular mass index, and urinary albumin
to creatinine excretion ratio, respectively (Diaz et al, 2014). Similarly, in a large,
multiethnic, probability-based population cohort in the Dallas Heart Study,
masked hypertension was associated with increased aortic stiffness, renal injury,
and cardiovascular events as measured from aortic pulse wave velocity, cystatin C,
and urinary albumin-to-creatinine ratio (Tientchu, 2015).
There is conflicting evidence on whether or not white-coat hypertension is
associated with higher cardiovascular risk. A study that investigated the
cardiovascular outcomes in sustained hypertension, white coat hypertension, and
normotension in the short and long term found increased cardiac and
cerebrovascular risk in patients with sustained hypertension, but no significant
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difference between this risk in patients with white coat hypertension versus
normotension (Pierdomenico et al., 2008).
More recent literature shows increasing evidence suggesting that white coat
hypertension results in poor cardiovascular outcomes. Similar to masked
hypertension, patients with white coat hypertension in the Dallas Heart Study were
identified to have evidence of target organ damage with increased aortic stiffness,
renal injury, and cardiovascular events (Tientchu, 2015). A comprehensive metaanalysis examining target organ damage and its association with white coat
hypertension found higher risk of cardiovascular disease and total mortality in
patients with untreated white coat hypertension (Huang et al., 2017). A recent
systematic review and meta-analysis published in the Annals of Internal Medicine
found that untreated white coat hypertension is associated with a near double risk
of cardiovascular events and all-cause mortality (Cohen et al., 2019).
Summary
The literature suggests that blood pressure screening strategies that rely
solely on clinic blood pressure readings will misdiagnose patients with or without
hypertension in regard to white coat and masked hypertension. Incorporating
ABPM or HBPM in hypertension screening is necessary to correctly diagnose
hypertensive phenotype. Almost all of the studies described in the literature review
were performed prior to the publication of the 2017 AHA and ACC guideline on
blood pressure management, therefore, data may actually underestimate the
prevalence of hypertension in the general population. The literature published after
the 2017 AHA and ACC guideline showed increasing evidence of poor
cardiovascular outcomes associated with white coat hypertension. The 2017
guideline lacks recommendations for treatment of white coat hypertension.
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The studies on provider and patient attitudes regarding ABPM and HBPM
are outdated, and no studies have been performed to address these barriers. Further
studies are needed to identify better screening parameters for masked
hypertension. There are no studies that evaluate the role of ABPM or HBPM in
guiding anti-hypertensive treatment. Studies are needed to examine treatment
options and outcomes specific to patients with masked hypertension and white
coat hypertension.

CHAPTER 3: METHODOLOGY
To address the problem of misdiagnosis of hypertension due to lack of
home blood pressure monitoring, Stanford Health Care implemented a quality
improvement project that provided patients with a home blood pressure device to
monitor out of clinic blood pressure readings. The purpose of the project was to
improve clinical care at Stanford Health Care by using home blood pressure
monitoring as a way to assess for treatment control in patients already diagnosed
with hypertension, or to verify the diagnosis of hypertension in patients not
previously diagnosed.
Stanford Health Care staff created a patient-centered, blood pressure
screening workflow mirroring the 2017 AHA and ACC Guideline for the
Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults. The Stanford School of Medicine sponsored 30 brachial Omron 10 series
blood pressure devices (Model: BP7450) to use for the quality improvement
project. This model had been inspected and cleared by the United States Food and
Drug Administration (FDA) and clinically validated according to protocols from
the European Society of Hypertension – International Protocol and the Association
for the Advancement of Medical Instrumentation (Omron, 2020).
The workflow was implemented on January 2, 2019. Data was collected
from the start of workflow implementation through August 31, 2019. Before
collecting data, clinical site permission and institutional review board approval
was obtained from both California State University (CSU) Fresno and Stanford
School of Medicine. The quality improvement project was exempt from full
review by the Committee for the Protection of Human Subjects from both CSU
Fresno and Stanford School of Medicine because the project involved the study of
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existing data, documents, and records routinely available to the investigator. Only
the minimum data necessary for project evaluation was collected. Data was deidentified and obtained from the patient electronic charts on-site on an encrypted
computer, only accessible to the investigator. After data analysis completed, the
collection log was permanently deleted. The data elements that were collected
were clinic blood pressure, clinic phenotype, mean home blood pressure, home
phenotype, age, sex, smoking status, BMI, alcohol status, whether the patient was
on treatment for hypertension or not, and the time (days) from clinic visit to
diagnosis and treatment plan.
Subjects
The subjects were full time employees of a large tech company. They all
had health insurance and received care at their employer-based health clinic
managed by Stanford Health Care. The professional spectrum included engineers,
scientists, lawyers, and business strategists, ages 23 to 66.
Inclusion Criteria
Because of the limited amount of home blood pressure monitors that were
available, the quality improvement project was limited to patients who presented
to the clinic for their routine preventative physical or for a blood pressure specific
complaint. Patients with a clinic blood pressure reading that was considered
elevated (SBP greater than 120 mmHg and a DBP greater than 75 mmHg) or high
(SBP greater than 130 mmHg or DBP greater than 80 mmHg) were considered for
inclusion (see Appendix A for workflow diagram). Patients excluded from
borrowing a blood pressure device from the clinic were patients with normal blood
pressures (SBP less than120 mmHg and DBP less than 80) and patients who
presented to the clinic for a problem-focused visit that was not blood pressure
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specific. Patients were given the option whether or not they wanted to utilize a
clinic provided home blood pressure monitor or purchase their own blood pressure
device for monitoring. Data was only collected from the patients who chose to
borrow the clinic blood pressure device.
Workflow
For patients who presented to the clinic with a blood pressure specific
complaint or for their routine preventative health physical, the patient was brought
into the clinic room and asked to sit quietly for five minutes. The medical assistant
took the patient’s blood pressure with Stanford Health Care electronic equipment.
If the clinic reading met the criteria for inclusion, the medical assistant
automatically re-checked the blood pressure with an Omron home blood pressure
monitoring device. Quality was accurate if the diastolic blood pressure was +/- 3
mmHg according to manufacturer standards. If the calibration was not according
to manufacturer standards, quality was checked on a different Omron device. After
verification that the Omron blood pressure device was correctly calibrated with the
electronic equipment, the medical assistant notified the provider that the patient
was ready for examination and eligible for HBPM based on clinic blood pressure
measurement.
During the office visit, the provider discussed the findings and implications
of elevated or high blood pressure with the patient, and the need for confirmation
of diagnosis through HBPM. Additionally, the patient was given instruction on
lifestyle changes to improve blood pressure measurements. The patient was given
the option to either purchase a blood pressure device or borrow the clinic Omron
cuff to obtain out of clinic blood pressure measurements in order to confirm
diagnosis of hypertension. The patient was then instructed on the proper way to
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take their blood pressure at home using the Omron blood pressure device. It was
recommended that the patient take three consecutive blood pressure readings. The
first reading was to be discarded, and the average of the second and third reading
was to be recorded into a blood pressure log. They were asked to do this twice
daily, preferably before breakfast and before dinner, for at least three consecutive
days after resting for five minutes.
For follow up, the patient had the option to schedule an in-office
appointment to review data and discuss results or send the data to the provider
through the EPIC MyHealth Tracker system. The MyHealth Tracker system
allowed the patient to input blood pressure data into their medical record, which
automatically sends to the primary care provider. Upon receipt of the data, the
primary care provider is able to calculate the mean home blood pressure. For
patients already on anti-hypertensive medication, a normal or elevated blood
pressure reading was considered controlled hypertension; a blood pressure in any
hypertensive category was considered uncontrolled hypertension. For patients who
had never been diagnosed with high blood pressure, the mean home blood
pressure measurement allowed the primary care provider to diagnose hypertensive
phenotype: normotension or elevated blood pressure, sustained hypertension,
white coat hypertension, or masked hypertension. All patients who participated in
the quality improvement project were given recommendations on lifestyle
changes. Pharmacologic intervention was recommended according to the AHA
and ACC 2017 guideline if indicated. The device was then returned to the clinic
by the patient. Any saved data was cleared from the device. The machine, cuff,
and tubing were wiped down with Sani-wipes, per policy.
.

CHAPTER 4: RESULTS
There were 114 patients who met the inclusion criteria for home blood
pressure monitoring between January 2, 2019 and August 31, 2019. Of these
patients, 16 were excluded from data analysis because they were still under
possession of the clinic cuffs upon data collection.
Sample Demographics
Data was obtained from 98 patients who participated in the quality
improvement project. The age range was between 23 and 66 years of age, with a
mean age of 44 (SD = 9.29). There were 10 female and 88 male participants. Of
the sample, there were 7 patients who were current cigarette smokers, 14 former
smokers, and 77 non-smokers. The BMI ranged from 16.54 to 42.69, with a mean
of 27.76 (SD = 4.77). Alcohol intake varied (see Figure 1).

Figure 1. Number of patients categorized by their reported average weekly alcohol
consumption in standard drinks per week.
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Of the 98 participants, 30% (n=29) already had the diagnosis of hypertension and
were on blood pressure medication while 70% (n=69) had never been diagnosed
with hypertension (see Figure 2).

Figure 2. Number of patients previously diagnosed with hypertension versus
number of patients with elevated blood pressure readings without the diagnosis of
hypertension.
Data Analysis
Patients who already the diagnosis of hypertension and were on antihypertensive medications were given home blood pressure monitors to assess for
treatment control. Patients who had never been diagnosed with hypertension were
given home blood pressure cuffs to confirm hypertensive phenotype. Therefore,
data analyses between these two groups were performed separately.
Patients Already Diagnosed with
Hypertension
Home blood pressure monitoring was implemented in 29 patients already
diagnosed with hypertension to assess for treatment control. After home blood
pressure monitoring, 31% (n=9) had controlled hypertension and 69% (n=20) had
uncontrolled hypertension (see Figure 3). The patients with controlled
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hypertension were advised to continue their current medication regimen and
lifestyle modifications were reinforced. All 20 patients who had uncontrolled
hypertension agreed to a medication dose change.

Figure 3. Of the patients already diagnosed with hypertension, the number of
patients with controlled hypertension versus uncontrolled hypertension after
completion of home blood pressure monitoring.
The number of days was documented from the patient’s clinic visit to when
a diagnosis and treatment plan was made. There was a clear outlier of 140 days for
unknown reason. Removing this outlier, the time (days) to treatment intervention
ranged from 3 to 35 day, with a mean (days) of 12.7 (SD = 8.27). The median was
11 days from clinic visit to diagnosis and treatment plan.
Patients Without the Diagnosis of
Hypertension
Home blood pressure monitoring was implemented in 69 patients who had
never been diagnosed with hypertension. After home blood pressure monitoring,
65% (n=45) had sustained hypertension, 20% (n=14) had white coat hypertension,
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and 12% (n=8) had elevated blood pressure or prehypertension (see Figure 4). No
patients had masked hypertension. Two patients were classified to have
normotension because they had elevated blood pressure readings at their clinic
visit with a normal mean home blood pressure reading.

Figure 4. Patients without the diagnosis of hypertension categorized by
hypertensive phenotype after the home blood pressure monitoring intervention.
There were 45 patients that were newly diagnosed with hypertension after
home blood pressure monitoring was completed. Of these patients, 67% (n=30)
had Hypertension Stage 1 and 33% (n=15) had Hypertension Stage 2. Of the
patients diagnosed with Hypertension Stage 1, 9 patients agreed to implement
medication therapy in addition to lifestyle modifications, and 21 patients opted to
work on lifestyle modifications with agreement to re-evaluate the treatment plan in
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3 to 6 months (see Figure 5). The time (days) from clinic visit to treatment
intervention ranged from 6 to 70 days, with a mean (days) of 16.8 (SD = 13.41),
and a median of 14 days. In the patients diagnosed with Hypertension Stage 2, 12
patients agreed to implement medication therapy in addition to lifestyle
modifications, and 3 patients opted to work on lifestyle modifications with
agreement to re-evaluate the treatment plan in 3 months. The time (days) from
clinic visit to treatment intervention ranged from 4 to 34 days, with a mean (days)
of 11.73 (SD = 8.67), and a median of 7 days (see Figure 5).

Figure 5. Number of patients newly diagnosed with hypertension according to
stage, and the treatment plan implemented after home blood pressure monitoring
was performed.

CHAPTER 5: DISCUSSION AND CONCLUSION
Discussion
Implementation of home blood pressure monitoring increased awareness of
the importance of hypertension and allowed for education of risk reduction
strategies in all 116 patients who met the inclusion criteria for the quality
improvement project. All patients who participated took away an understanding of
what their blood pressure readings meant and how to make healthy lifestyle
choices to reduce their cardiovascular risk.
Home blood pressure monitoring was used to assess for treatment control in
patients already diagnosed with hypertension. All of the patients on antihypertensive medications diagnosed with uncontrolled hypertension agreed to a
medication dose change. This suggests that home blood pressure monitoring was
not only effective in assessing for treatment control, but it helped allow the patient
to recognize the need for treatment adjustment to improve control.
Home blood pressure monitoring was also used to evaluate hypertensive
phenotype in patients undiagnosed with hypertension. Home blood pressure was
very useful in verifying the hypertensive phenotype in patients with sustained
hypertension and white coat hypertension. Of the 69 patients undiagnosed with
hypertension, over half of them (65%, n=45) were confirmed to have sustained
hypertension. The percentage of patients diagnosed with white coat hypertension
(20%) was consistent with the epidemiologic data estimate of 15% to 30% of the
United States population having white coat hypertension. Furthermore, of the 45
patients newly diagnosed with hypertension, home blood pressure monitoring
prompted 46% (n=21) to initiate medication therapy. This suggests that home
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blood pressure monitoring may have had a positive role in patient recognition and
acceptance of diagnosis.
The most profound impact of providing patients with home blood pressure
monitors was the turnaround time from clinic visit to diagnosis and treatment plan.
Anecdotally, in the investigator’s practice, it could take months to years to confirm
whether or not a patient had sustained hypertension versus white coat hypertension
prior to implementation of this quality improvement project. By providing a
patient with a clinic loaned blood pressure device, a diagnosis and treatment plan
was made, on average, within two weeks.
Limitations
This was a quality improvement project; therefore, the author is unable to
statistically quantify the significance of findings. It was made very clear to CSU
Fresno and Stanford School of Medicine that the undertaking was a quality
improvement project with the purpose of implementing a data-guided intervention
to bring immediate improvements in health delivery as opposed to research
designed to contribute to generalizable knowledge. Because this was not a
research study, the investigator is unable to correlate any associations between
hypertension and alcohol consumption, BMI, or cigarette smoking.
Of the 114 patients who participated in the project, 16 of them were
excluded because they still possessed the clinic cuffs at the start of data collection.
Unfortunately, due to limited overhead, it was very difficult to track and request
the return of these cuffs. Project data did not include the patients who chose to use
their own home blood pressure devices. Lastly, Stanford School of Medicine
sponsored 30 Omron blood pressure devices to implement the quality
improvement project; therefore, for clinics interested in replicating the project,
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there may be a cost barrier to obtain a supply of blood pressure devices for their
clinic.
Future Recommendations
The ability to monitor blood pressure readings outside of the clinic
environment is continuously developing. With the push toward home blood
pressure or ambulatory blood pressure monitoring, the diagnosis of hypertension
depends on blood pressure variation throughout the day. In addition to ambulatory
and home blood pressure monitoring, there are devices available that have the
capacity to automatically transmit blood pressure reading directly into the patient’s
medical record. There are newer devices yet to be FDA approved where the
patient wears a patch on their chest that can monitor their blood pressure, heart
rhythm, and their blood oxygen saturation
This quality improvement project alone has great potential for expansion.
The positive results have already prompted interest for sponsorship of more blood
pressure devices. Future analyses can focus on provider and patient attitudes
regarding home blood pressure monitoring. Investigation of home blood pressure
monitoring in guiding anti-hypertensive treatment is also promising. The United
States healthcare system is complex and rapidly evolving as more and more clinics
are increasing services through telemedicine. Several patients in this project chose
to report their home blood pressure readings to the provider through the MyHealth
tracker; it is possible to create a fully-telehealth workflow for blood pressure
management.
Conclusion
Management of hypertension is a public health challenge. Without home
blood pressure monitoring, it is impossible to correctly diagnose and treat
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hypertension, which is essential for hypertension management. Providing patients
with a home blood pressure monitor is a simple and effective way to assess for
treatment control in patients already diagnosed with hypertension and to validate
hypertensive phenotype in patients undiagnosed with hypertension, particularly
with white coat hypertension and sustained hypertension. Furthermore, it allows
the patients to become active participants in their health and increases awareness
of the silent killer known as hypertension. Providing home blood pressure
monitors as a screening tool for hypertension has the potential to reduce morbidity
and mortality, reduce economic burden, and contribute to national quality
initiatives that contribute to the overall health of the nation.

REFERENCES

References

American Heart Association (2016, October 31). Health Threats from High Blood
Pressure. Retrieved from: https://www.heart.org/en/health-topics/high-bloodpressure/health-threats-from-high-blood-pressure.
American Heart Association (2017, December 31). Know Your Risk Factors for
High Blood Pressure. Retrieved from:https://www.heart.org/en/healthtopics/high-blood-pressure/why-high-blood-pressure-is-a-silent-killer/knowyour-risk-factors-for-high-blood-pressure.
Bloomfield, D. A., & Park, A. (2017). Decoding white coat hypertension. World
journal of clinical cases, 5(3), 82.
Bonafini, S., & Fava, C. (2015). Home blood pressure measurements: advantages
and disadvantages compared to office and ambulatory monitoring. Blood
pressure, 24(6), 325-332.
Booth III, J. N., Muntner, P., Diaz, K. M., Viera, A. J., Bello, N. A., Schwartz, J.
E., & Shimbo, D. (2016). Evaluation of criteria to detect masked
hypertension. The Journal of Clinical Hypertension, 18(11), 1086-1094.
Bromfield, S. G., Shimbo, D., Booth III, J. N., Correa, A., Ogedegbe, G., Car.son,
A. P., & Muntner, P. (2016). Cardiovascular risk factors and masked
hypertension: the Jackson Heart Study. Hypertension, 68(6), 1475-1482.

35

Carter, E. J., Moise, N., Alcántara, C., Sullivan, A. M., & Kronish, I. M. (2018).
Patient barriers and facilitators to ambulatory and home blood pressure
monitoring: a qualitative study. American journal of hypertension, 31(8),
919-927.
Centers for Disease Control and Prevention. (2013). Self-Measured Blood
Pressure Monitoring: Action Steps for Public Health Practitioners. US Dept
of Health and Human Services.
Centers for Disease Control (2016). High Blood Pressure Facts. Retrieved from
https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_bloodpressure.htm.
Cheng, C., Studdiford, J. S., Diamond, J. J., & Chambers, C. V. (2003). Primary
care physician beliefs regarding usefulness of self-monitoring of blood
pressure. Blood pressure monitoring, 8(6), 249-254.
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo
Jr, J. L., ... & Roccella, E. J. (2003). The seventh report of the joint national
committee on prevention, detection, evaluation, and treatment of high blood
pressure: the JNC 7 report. Jama, 289(19), 2560-2571.
Cohen, J. B., Lotito, M. J., Trivedi, U. K., Denker, M. G., Cohen, D. L., &
Townsend, R. R. (2019). Cardiovascular events and mortality in white coat
hypertension: a systematic review and meta-analysis. Annals of internal
medicine, 170(12), 853-862.

36

Diaz, K. M., Veerabhadrappa, P., Brown, M. D., Whited, M. C., Dubbert, P. M., &
Hickson, D. A. (2014). Prevalence, determinants, and clinical significance of
masked hypertension in a population-based sample of African Americans:
the Jackson Heart Study. American journal of hypertension, 28(7), 900-908.
Franklin, S. S., O’Brien, E., Thijs, L., Asayama, K., & Staessen, J. A. (2015).
Masked hypertension: a phenomenon of measurement. Hypertension, 65(1),
16-20.
Glanz, K., Burke, L.E., & Rimer, B. (2018). Health behavior theories. In J.B. Butts
and K.L. Rich (Eds.), Philosophies and Theories. Burlington, MA: Jones &
Bartlett Learning.
Grassi, G., Seravalle, G., Buzzi, S., Magni, L., Brambilla, G., Quarti-Trevano, F.,
... & Mancia, G. (2013). Muscle and skin sympathetic nerve traffic during
physician and nurse blood pressure measurement. Journal of
hypertension, 31(6), 1131-1135.
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K.,
Ezekowitz, M. D., ... & Lloyd-Jones, D. M. (2011). Forecasting the future of
cardiovascular disease in the United States: a policy statement from the
American Heart Association. Circulation, 123(8), 933-944.
Hochbaum, G., Rosenstock, I., & Kegels, S. (1952). Health belief model. United
States Public Health Service.
Huang, Y., Huang, W., Mai, W., Cai, X., An, D., Liu, Z., ... & Xu, D. (2017).
White-coat hypertension is a risk factor for cardiovascular diseases and total
mortality. Journal of hypertension, 35(4), 677.

37

James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C.,
Handler, J., ... & Smith, S. C. (2014). 2014 evidence-based guideline for the
management of high blood pressure in adults: report from the panel members
appointed to the Eighth Joint National Committee (JNC 8). Jama, 311(5),
507-520.
Kamran, A., Ahari, S. S., Biria, M., Malpour, A., & Heydari, H. (2014).
Determinants of patient’s adherence to hypertension medications: application
of health belief model among rural patients. Annals of medical and health
sciences research, 4(6), 922-927.
Kent, S. T., Shimbo, D., Huang, L., Diaz, K. M., Viera, A. J., Kilgore, M., ... &
Muntner, P. (2014). Rates, amounts, and determinants of ambulatory blood
pressure monitoring claim reimbursements among Medicare
beneficiaries. Journal of the American Society of Hypertension, 8(12), 898908.
Kleinert, H. D., Harshfield, G. A., Pickering, T. G., Devereux, R. B., Sullivan, P.
A., Marion, R. M., ... & Laragh, J. H. (1984). What is the value of home
blood pressure measurement in patients with mild
hypertension?. Hypertension, 6(4), 574-578.
Kronish, I. M., Kent, S., Moise, N., Shimbo, D., Safford, M. M., Kynerd, R. E., ...
& Muntner, P. (2017). Barriers to conducting ambulatory and home blood
pressure monitoring during hypertension screening in the United
States. Journal of the American Society of Hypertension, 11(9), 573-580.

38

Landsbergis, P. A., Dobson, M., Koutsouras, G., & Schnall, P. (2013). Job strain
and ambulatory blood pressure: a meta-analysis and systematic
review. American journal of public health, 103(3), e61-e71.
Logan, A. G., Dunai, A., McIsaac, W. J., Irvine, M. J., & Tisler, A. (2008).
Attitudes of primary care physicians and their patients about home blood
pressure monitoring in Ontario. Journal of hypertension, 26(3), 446-452.

Muntner, P., Carey, R. M., Gidding, S., Jones, D. W., Taler, S. J., Wright Jr, J. T.,
& Whelton, P. K. (2018). Potential US population impact of the 2017
ACC/AHA high blood pressure guideline. Circulation, 137(2), 109-118.
National Center for Health Statistics (2015). Presence of selected chronic
conditions at office visits, by patient age and sex: United States, 2015.
National Ambulatory Medical Care Survey. Retrieved from
https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2015_namcs_web_tabl
es.pdf.
National Institute for Health and Care Excellence Guideline (2019, March).
Guideline: Hypertension in adults: diagnosis and management: Draft for
consultation. Retrieved from https://www.nice.org.uk/guidance/gidng10054/documents/draft-guideline.
Office of Disease Prevention and Health Promotion (2019). Heart Disease and
Stroke Objectives. Retrieved from
https://www.healthypeople.gov/2020/topics-objectives/topic/heart-diseaseand-stroke/objectives.

39

Omron Health Care (2020.) Clinical Validation – Omron Healthcare. Retrieved
from https://omronhealthcare.com/service-and-support/clinical-validation/.
Peacock, J., Diaz, K. M., Viera, A. J., Schwartz, J. E., & Shimbo, D. (2014).
Unmasking masked hypertension: prevalence, clinical implications,
diagnosis, correlates and future directions. Journal of human
hypertension, 28(9), 521.
Pickering, T. G., Davidson, K., Gerin, W., & Schwartz, J. E. (2002). Masked
hypertension.
Pierdomenico, S. D., Lapenna, D., Di Mascio, R., & Cuccurullo, F. (2008). Shortand long-term risk of cardiovascular events in white-coat
hypertension. Journal of human hypertension, 22(6), 408-414.
Piper, M. A., Evans, C. V., Burda, B. U., Margolis, K. L., O'Connor, E., &
Whitlock, E. P. (2015). Diagnostic and predictive accuracy of blood pressure
screening methods with consideration of rescreening intervals: a systematic
review for the US Preventive Services Task Force. Annals of internal
medicine, 162(3), 192-204.
Redmond, N., Booth, J., Tanner, R., Diaz, K., Abdalla, M., Sims, M., . . . Shimbo,
D. (2016). Prevalence of Masked Hypertension and Its Association With
Subclinical Cardiovascular Disease in African Americans: Results From the
Jackson Heart Study. Journal of the American Heart Association, 5(3), N/a.
Rosenstock, I. M. (1974). Historical origins of the health belief model. Health
Education Monographs, 2(4), 328-335.

40

Schultz, M. G., Hare, J. L., Marwick, T. H., Stowasser, M., & Sharman, J. E.
(2011). Masked hypertension is “unmasked” by low-intensity exercise blood
pressure. Blood pressure, 20(5), 284-289.
Schwartz, J. E., Burg, M. M., Shimbo, D., Broderick, J. E., Stone, A. A., Ishikawa,
J., ... & Pickering, T. G. (2016). Clinic blood pressure underestimates
ambulatory blood pressure in an untreated employer-based US population:
results from the Masked Hypertension Study. Circulation, 134(23), 17941807.
Sharman, J. E., Hare, J. L., Thomas, S., Davies, J. E., Leano, R., Jenkins, C., &
Marwick, T. H. (2011). Association of masked hypertension and left
ventricular remodeling with the hypertensive response to exercise. American
journal of hypertension, 24(8), 898-903.
Shimbo, D., Abdalla, M., Falzon, L., Townsend, R. R., & Muntner, P. (2015).
Role of ambulatory and home blood pressure monitoring in clinical practice:
a narrative review. Annals of internal medicine, 163(9), 691-700.
Shimbo, D., Newman, J., & Schwartz, J. (2012). Masked hypertension and
prehypertension: Diagnostic overlap and interrelationships with left
ventricular mass: The masked hypertension study. American Journal of
Hypertension, 25(6), 664-671.
Siu, A. L. (2015). Screening for high blood pressure in adults: US Preventive
Services Task Force recommendation statement. Annals of internal
medicine, 163(10), 778-786.

41

Tanner, R. M., Shimbo, D., Seals, S. R., Reynolds, K., Bowling, C. B., Ogedegbe,
G., & Muntner, P. (2016). White‐Coat Effect Among Older Adults: Data
From the Jackson Heart Study. The Journal of Clinical Hypertension, 18(2),
139-145.
Thalacker, K. M. (2011). Hypertension and the hmong community: using the
health belief model for health promotion. Health promotion practice, 12(4),
538-543.
Tientcheu, Ayers, Das, Mcguire, De Lemos, Khera, . . . Vongpatanasin. (2015).
Target Organ Complications and Cardiovascular Events Associated With
Masked Hypertension and White-Coat Hypertension: Analysis From the
Dallas Heart Study: Analysis From the Dallas Heart Study. Journal of the
American College of Cardiology, 66(20), 2159-2169.
Tirabassi, J., Fang, J., & Ayala, C. (2013). Attitudes of primary care providers and
recommendations of home blood pressure monitoring—DocStyles, 2010. The
Journal of Clinical Hypertension, 15(4), 224-229.
Viera, A. J., Lingley, K., & Hinderliter, A. L. (2011). Tolerability of the Oscar 2
ambulatory blood pressure monitor among research participants: a crosssectional repeated measures study. BMC medical research
methodology, 11(1), 59.
Wang, Y. C., Shimbo, D., Muntner, P., Moran, A. E., Krakoff, L. R., & Schwartz,
J. E. (2017). Prevalence of masked hypertension among US adults with
nonelevated clinic blood pressure. American journal of epidemiology, 185(3),
194-202.

42

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J.,
Himmelfarb, C. D., ... & MacLaughlin, E. J. (2018). 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
guideline for the prevention, detection, evaluation, and management of high
blood pressure in adults: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. Journal of the American College of Cardiology, 71(19), e127e248.
White, William B, & Gulati, Vinay. (2015). Managing Hypertension with
Ambulatory Blood Pressure Monitoring. Current Cardiology Reports., 17(2),
2.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M.,
... & Kahan, T. (2018). 2018 ESC/ESH Guidelines for the management of
arterial hypertension. European heart journal, 39(33), 3021-3104.
World Health Organization (2019). Global Health Observatory (GHO) data:
Raised blood pressure. Retrieved from
https://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/e
n/.

APPENDICES
APPENDIX A: HYPERTENSION SCREENING WORKFLOW

